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Abstract
Melatonin receptor expression exhibits profound developmental changes through poorly understood mechanisms. In
mammals, a current model suggests that pubertal reactivation of gonadotrophin-releasing hormone (GnRH) secretion
down-regulates MT1 melatonin receptors in pituitary gonadotroph cells, via the induction of early growth response factor-1
(EGR-1). Here we have examined this model by testing the hypotheses that inhibition of Mt1 expression by GnRH occurs
directly in gonadotroph cells, can be reversed in adulthood by blockade of GnRH receptors, and requires EGR-1. We first
confirmed the endogenous expression of Mt1 mRNA in the aT3-1 gonadotroph cell line. Stimulation of these cells with a
GnRH agonist resulted in a rapid increase of Egr-1 mRNA expression, which peaked after 30–60 minutes, and a more
prolonged elevation of nuclear EGR-1 immunoreactivity. Moreover, the GnRH agonist significantly decreased Mt1 mRNA. We
then treated adult male rats with the GnRH antagonist cetrorelix or saline. After 4 weeks of daily injections, cetrorelix
significantly reduced serum LH concentration and testis weight, with histological analysis confirming absence of
spermatogenesis. Despite the successful inhibition of GnRH signalling, pituitary Mt1 expression was unchanged. Next we
studied the proximal region of the rat Mt1 promoter. Consistent with previous work, over-expression of the transcription
factor PITX-1 increased Mt1-luciferase reporter activity; this effect was dependent on the presence of consensus PITX-1
promoter binding regions. Over-expression of EGR-1 inhibited PITX-1-stimulated activity, even following mutation of the
consensus EGR-1 binding site. Finally, we studied Egr12/2 mice and observed no difference in pituitary Mt1 expression
between Egr12/2 and wild-type litter mates. This work demonstrates that GnRH receptor activation directly down-regulates
Mt1 expression in gonadotroph cells. However, pituitary Mt1 expression in adults is unaltered by blockade of GnRH
signalling or absence of EGR-1. Our data therefore suggest that melatonin receptor regulation by GnRH is not reversible in
adulthood and doesn’t require EGR-1.
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Introduction
The hormone melatonin is implicated in multiple diverse
aspects of physiology [1]. It is secreted into the blood and
cerebrospinal fluid by the pineal gland, and is produced locally by
other tissues within the body, such as the retina [2]. In mammals,
melatonin signals through two receptors of the G-protein-coupled
super-family, termed MT1 and MT2 [3]. Compared to adults,
foetuses and neonates exhibit a more widespread receptor
distribution, suggesting that melatonin may have as yet unknown
roles in development [4]. Surprisingly little is known about the
mechanisms controlling these developmental changes in melatonin
signalling.
Pineal melatonin production is driven by the master circadian
clock in the suprachiasmatic nuclei of the hypothalamus and thus
exhibits a robust daily rhythm. This rhythm varies in proportion to
the length of the night and so melatonin encodes both daily and
seasonal time [5]. In mammals, melatonin is essential for
photoperiodic physiology and can regulate circadian clock gene
expression in several peripheral tissues [6–9], indicating a possible
ability to synchronise peripheral circadian clocks. In addition to
control of rhythmic physiology, melatonin is also reported to
control many other biological processes. One of these is
suppression of the endocrine response of the developing pituitary
gland to the key reproductive factor, gonadotrophin-releasing
hormone (GnRH) [10]. This effect disappears in the postnatal
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rodent pituitary gland and thus may be relevant to the timing of
puberty [11–13]. Interestingly, melatonin secretion has been
associated with reproductive development and the timing of
human puberty in some studies [14–16]. However aspects of this
work has methodological flaws [14,15] and other studies have
failed to replicate the finding [17,18].
We have previously studied the regulation of MT1 melatonin
receptors in the pituitary gland and suggested a mechanism
controlling MT1 expression during reproductive development. In
our model, Mt1 promoter activity is stimulated by the transcription
factor pituitary homeobox-1 (PITX-1) [19–21]. During early
stages of development, PITX-1-stimulation of Mt1 is thought to be
inhibited by factors involved in Rathke’s Pouch proliferation, such
as MSX-1 [22]. Consistent with this hypothesis, the decline in
Msx-1 coincides with the onset of Mt1 expression in the foetal rat
pituitary. Following a period of melatonin sensitivity, it is proposed
that the pubertal reactivation of GnRH secretion then finally
down-regulates Mt1 expression, likely via induction of early
growth response factor-1 (EGR-1; also known as NGFI-A and
Krox-24) [20,21].
This model received preliminary support from the observation
that adult hypogonadal mice, which are unable to synthesise GnRH,
exhibit elevated levels of Mt1 expression than their wild type
controls [20]. However, the model is yet to be thoroughly tested.
In particular, it is unclear whether GnRH directly regulates
gonadotroph MT1 expression, whether the inhibitory effects of
GnRH require EGR-1 and are reversible in adulthood. Here, we
have addressed these questions using a combination of in vivo and
in vitro techniques. As in previous work by ourselves and others,
much of the data derives from the rat, in which developmental
changes of Mt1 are most extensively characterised. Due to the
availability of suitable gonadotroph cell lines and transgenic
‘knockout’ animals, other parts of the study have used mouse
tissue. Such an approach takes advantage of the benefits of each
system and has been used successfully before, e.g. [20].
Methods
Cell culture and transient transfection assays
Unless otherwise specified, all cells were cultured at 37uC and
5% CO2 in growth medium: DMEM (Invitrogen Ltd, Paisley,
UK) supplemented with 10% fetal bovine serum (Invitrogen),
antibiotic/antimycotic (Invitrogen), and sodium pyruvate (Sigma-
Aldrich Co Ltd, Poole, UK). Data shown are from a representative
of at least three independent experiments.
For studies of GnRH signalling, aT3-1 cells [23] were seeded in
6 well plates at a density of 300,000 cells per well. After 24 hours,
cells were treated with GnRH agonist ([des-Gly10, D-ala
6 ]-LH-
RH ethylamide acetate salt hydrate; Sigma-Aldrich) at final
concentration of 100 nM. After the required treatment time(s),
cells were harvested for analysis of mRNA by TaqMan real-time
PCR or protein by western blot, as described below.
For studies of rat Mt1 promoter activity, COS-7 cells (ATCC;
LGC Standards, Teddington UK) were seeded in 96 well plates at
a density of 3,500 cells per well. After 24 hours, cells were
transfected using FuGene6 reagent (Roche Diagnostics Ltd,
Burgess Hill, UK), according to the manufacturer’s protocol.
Each well received DNA containing 5 ng of MT1-luciferase
reporter plasmid, and appropriate expression vectors, made up to
a total of 50 ng with pcDNA3. Forty-eight hours after transfection,
reporter gene activity was measured using the Dual-Glo system
(Promega UK, Southampton, UK). Each treatment was per-
formed in quadruplicate wells per experiment. Rat Mt1-luciferase
plasmids were based on the 2445 bp vector described previously
[20]. Additional plasmids were manufactured by Eurofins MWG
Operon (Ebersberg, Germany) to include mutation in the EGR-1
or one of the two PITX-1 binding sites described previously
[19,20]. The distal PITX-1 site (P1) was modified from TCATCC
to TGGCGC; the proximal PITX-1 site (P2) was modified from
TAATCC to TGGCGC; the EGR-1 site was modified from
AGGCGCGGGAGG to AGGCTCTTTAGG.
Ethics Statement
Experiments using rats were performed in accordance with the
UK Animals (Scientific Procedures) Act, 1986, under licence from
the UK Home Office (PPL 70/7059). Experiments were also
approved by the University of Surrey’s Animal Welfare Ethical
Review Board. All experimental work with mice was conducted in
accordance with the European Communities Council Directive
86/609/EEC and the French National Committee (87/848). No
surgical procedures were undertaken in this study. Animal
suffering was minimised by sacrificing animals according to
approved procedures (rising concentration of CO2, cervical
dislocation).
Animals
Twelve 10-week old male Wistar rats were obtained from
Charles River UK. After acclimation to the experimental facility,
rats were treated for 4 weeks with daily i.p. injections of either
100 mg GnRH antagonist (cetrorelix acetate; Merck Serono,
Feltham, UK) or saline control (n = 6 animals per group, based
on in situ hybridisation data comparing hypogonadal and wild
type adult mice [20]). Injections were given between 10:00–11:00
each day. Experimental groups were weight-matched and
individual animals housed in separate cages under a 12-hour
light: 12-hour dark cycle with ad libitum access to food and water.
Following the treatment period, rat brains and pituitaries were
dissected together, keeping the pituitary stalks intact, and frozen
on dry ice prior to analysis by in situ hybridisation histochemistry.
Serum samples were collected for luteinising hormone (LH)
analysis. Both testes from each animal were weighed and frozen on
dry ice prior to histological analysis. All samples were stored at
280uC.
Egr-12/2 mice and wild type littermates were bred in an
established colony at Universite´ Paris-Sud, described elsewhere
[24]. Brains and pituitaries from adult mice were dissected
together, keeping the pituitary stalks intact, and frozen on dry ice
prior to analysis by in situ hybridisation histochemistry. The
number of animals used for analysis (n = 7 per genotype) was based
on in situ hybridisation data comparing hypogonadal and wild
type adult mice [20].
Serum LH analysis
Serum LH was measured using a rodent LH ELISA kit
(Endocrine Technologies, INC. Newark, CA, USA), according to
the manufacturer’s instructions. In brief, 50 ml of sample or
standard was mixed with 100 ml of enzyme conjugate and
incubated at 37uC for 2 hours. Assay plate wells were rinsed
before 100 ml of TMB solution was added and incubated at room
temperature for 20 mins, in the dark. Finally the reaction was
stopped by adding 50 ml of 2N HCl and the optical density was
measured at 450 nm using a microtiter well reader. Concentration
of LH was calculated from the standard curve.
Testis histology
Sections of frozen testis (7 mm) were prepared and post-fixed
with ice-cold 4% paraformaldehyde for 10 mins then processed for
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hematoxylin and eosin staining. Sections were examined for
general morphology using light microscopy.
In situ hybridisation histochemistry
Analysis of Mt1 mRNA expression in brain/pituitary sections
was performed using a well validated assay, as described previously
[20]. In brief, 20 mm sagittal sections of brain and pituitary tissue
were hybridised with a 35S-labelled riboprobe corresponding to
nucleotides 30–466 of GenBank accession number U14409.
Hybridisation signal was quantified against optical density
standards on each autoradiography film.
TaqMan real-time PCR
After treatment, cells were washed twice with warmed 16PBS.
Total RNA extraction and cDNA synthesis were performed as
described previously [25]. Expression of mRNA for Mt1, Egr-1 and
Gapdh was measured using TaqMan RT-PCR [25]. Mt1 forward
primer: 59-TCTGCTACGTGTTCCTGATATGGAT-39; Mt1 re-
verse primer: 59-TGGAGTGTTCCGGTTTGCA-39; Mt1 probe:
59(FAM)-CTGACACTCATCGCCATCATGCCC-39(TAM); Egr-
1forward primer: 59-CCTTTTCTGACATCGCTCTGAA-39;




Cytoplasmic and nuclear-enriched protein was extracted from
cells using the NE-PER kit (Thermo Scientific, Cramlington, UK).
From each sample, 30 mg of total protein was separated on a 10%
polyacrylamide gel. Protein was transferred from gels to methanol-
activated PVDF membranes, which were then incubated in wash
buffer (TRIS-buffered saline containing 0.1% TWEEN 20;
365 minutes at room temperature), blocking buffer (5% skimmed
milk powder in wash buffer; 60 minutes at room temperature),
and wash buffer (365 minutes at room temperature).
Membranes were incubated with 1:200 dilution of anti-EGR-1
antibody (Egr-1 (588); Santa Cruz Biotechnology Inc, Heidelberg,
Germany) in blocking buffer for 60 minutes at room temperature.
After rinsing in wash buffer (365 minutes, room temperature),
membranes were then incubated with a 1:5000 dilution of
horseradish peroxidase-coupled anti-rabbit secondary antibody
(Sigma-Aldrich) in blocking buffer for 60 minutes at room
temperature. Next, membranes were rinsed in wash buffer
(165 minutes, room temperature) and protein expression detected
using the enhanced chemiluminescence (ECL; GE Healthcare,
UK) system according to the manufacturer’s protocol.
Following detection of EGR-1 protein, membranes were briefly
rinsed in ddH2O and wash buffer, before being incubated in strip
buffer (25 mM glycine, 1% SDS; 25 minutes, room temperature)
and wash buffer (265 minutes, room temperature). Non-specific
binding was blocked as described above and membranes were
then incubated with 1:2000 dilution of anti-actin antibody (Sigma-
Aldrich) in blocking buffer for 60 minutes at room temperature.
Washing, secondary antibody incubation and ECL detection were
then performed as described above.
Statistics
Quantitative data are presented as mean 6 SEM and were
analysed by either unpaired t-test or one-way ANOVA with
Bonferroni post-hoc test, as appropriate. Units of analysis were
data from either one animal or one well of cells. Statistical
significance was defined as p,0.05.
Results
Regulation of Egr-1 and Mt1 by GnRH agonist treatment
of aT3-1 gonadotroph cells
Treatment of aT3-1 cells with GnRH agonist induced a
significant (p,0.001, one-way ANOVA) induction of Egr-1
mRNA expression (Fig. 1A). Maximal expression was observed
after stimulation for 30 minutes, with a partial decline apparent
30 minutes later. In unstimulated cells, there was a faint band of
EGR-1 immunoreactivity at approximately 50 kDa in both
cytoplasmic and nuclear-enriched samples (Fig. 1B). Following
stimulation, there was little change in cytoplasmic EGR-1
expression; however, analysis of nuclear protein revealed increased
Figure 1. GnRH agonist treatment induces EGR-1 and inhibits
Mt1 expression in aT3-1 gonadotroph cells. Cells were treated
with 100 nM GnRH agonist for the specified times before molecular
analysis. (A) Total mRNA was extracted for analysis of Egr-1 mRNA,
expressed relative to Gapdh, by qRT-PCR. *** p,0.001 vs time 0 (one-
way ANOVA with Bonferroni post-hoc test). (B) Cytoplasmic and
nuclear-enriched lysates were prepared for analysis of EGR-1 and actin
protein expression by western blot. (C) Following 20 hours of GnRH
agonist treatment, total mRNA was extracted for analysis of Mt1 mRNA,
expressed relative to Gapdh, by qRT-PCR. * p,0.05 control vs treated
group (unpaired t-test).
doi:10.1371/journal.pone.0090056.g001
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expression of the 50 kDa band at 2 hours, with strong expression
of an approximately 65 kDa band of immunoreactivity between
2–8 hours. Finally, 20 hours after onset of GnRH agonist
treatment, there was a significant (p,0.05, unpaired t-test)
decrease in Mt1 mRNA expression (Fig. 1C). No significant
decline of Mt1 mRNA expression was observed at earlier time
points (data not shown).
Treatment of rats with GnRH receptor antagonist
Daily injection of rats with cetrorelix impaired reproductive
function, as revealed by a significant (p,0.001, unpaired t-test)
reduction of both serum LH concentration (saline: 6.2660.58 ng/
ml; cetrorelix: 1.0360.18 ng/ml; Fig. 2A) and paired testis weight
(4.7560.57 g; cetrorelix: 0.9560.03 g; Fig. 2B). On histological
analysis, all testes from saline-treated rats exhibited seminiferous
tubules full of developing spermatozoa, whereas testes from
cetrorelix-treated individuals exhibited smaller seminiferous tu-
bules in which there was no evidence of spermatogenesis (Fig. 2C).
Expression of Mt1 mRNA was analysed by in situ hybridisation
of sagittal sections through brain and pituitary tissue. In both
treatment groups, strong pituitary expression was observed in the
pars tuberalis and along the rostral extent of the ventral pars
distalis; weaker expression was observed throughout the rest of the
pars distalis (Fig. 2D). Quantification of pituitary Mt1 expression
revealed no significant difference (p.0.05, unpaired t-test) in
densitometry between the two treatment groups (saline: 1.1160.10
OD units; cetrorelix: 1.1260.11 OD units; Fig. 2E).
Molecular analysis of rat Mt1 promoter activity in vitro
Activity of the unmodified Mt1 promoter was significantly
(p,0.001, one-way ANOVA) modified by experimental condi-
tions (Fig. 3A), such that co-transfection with PITX-1 expression
vector alone significantly (p,0.001, Bonferroni post-hoc test)
increased promoter activity compared to the control group.
Mutation of either of the PITX-1 consensus sequences abolished
the ability of PITX-1 to stimulate the Mt1 promoter, as there was
no significant (p.0.05) difference in promoter activity between
control and PITX-1-stimulated groups (Fig. 3B and 3C).
Following mutation of the EGR-1 consensus sequence, there was
again a significant (p,0.001, one-way ANOVA) effect of co-
transfection conditions on Mt1 promoter activity; specifically,
PITX-1 stimulated the Mt1 promoter and EGR-1 remained able
to inhibit PITX-1-stimulated activity (p,0.001, Bonferroni post-
hoc test; Fig. 3D).
Expression of Mt1 mRNA in the pituitary of Egr-12/2 mice
Sagittal sections of brain and pituitary tissue from Egr-12/2
mice and wild type litter mates were analysed by in situ
hybridisation. In mice of both genotypes, faint Mt1 expression
was observed in the pituitary pars tuberalis region. However,
quantification revealed no significant difference (p.0.05, unpaired
t-test) in densitometry between the two genotypes (wild type:
0.1760.02 OD units; Egr12/2: 0.1560.02 OD units; Fig. 4).
Figure 2. Treatment of rats with GnRH antagonist impairs reproductive status but does not affect Mt1 expression. Male Wistar rats
were given a daily i.p. injection of the GnRH antagonist cetrorelix (100 mg/day) or saline control for 4 weeks. (A) Serum LH was measured by ELISA. (B–
C) Testis morphology was assessed by (B) paired testis weight and (C) histological analysis of tissue sections using hematoxylin and eosin staining.
Scale bar = 25 mm (D–E) Brain and pituitary tissue from saline and cetrorelix-treated rats was dissected with the pituitary stalk intact, frozen on dry ice
and stored at 280uC. Twenty micron sagittal sections were cut and Mt1 mRNA expression determined by in situ hybridisation histochemistry. (D)
Representative autoradiographs. In both treatment groups, strong pituitary expression was observed in the pars tuberalis and along the rostral
extent of the ventral pars distalis; weaker expression was observed throughout the rest of the pars distalis. (E) Quantification of Mt1 expression by
densitometry. *** p,0.001 saline vs cetrorelix group (unpaired t-test). Sal: saline-treated; Cet: cetrorelix-treated.
doi:10.1371/journal.pone.0090056.g002
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Discussion
This study demonstrates that activation of GnRH receptors in
gonadotroph cells down-regulates expression of Mt1 mRNA.
Despite this, functional blockade of GnRH receptors in adult rats
for 4 weeks fails to alter in vivo expression of Mt1. In transient
transfection assays, over-expression of EGR-1 inhibits PITX-1-
stimulated rat Mt1 promoter activity independently of an EGR-1
consensus sequence. However, there is no difference in pituitary
Mt1 expression in Egr-12/2 mice and wild type controls.
Our previous studies led us to hypothesise that the perinatal
decline in pituitary MT1 melatonin receptor expression is due to
the pubertal reactivation of GnRH secretion from the hypothal-
amus. We therefore first studied Mt1 expression in murine aT3-1
gonadotroph cells, which model newly differentiated gonadotrophs
as they express the common glycoprotein alpha subunit (aGSU)
and functional GnRH receptors, but not the LH beta subunit
[23,26]. Here, we demonstrate that aT3-1 cells also express Mt1
mRNA, making them an ideal model to study the interaction
between GnRH and endogenous melatonin receptors. As
described previously, stimulation of aT3-1 cells with a GnRH
agonist rapidly induces transient expression of Egr-1 mRNA [27],
with a more prolonged induction of EGR-1 protein in nuclear-
enriched extracts. Following this induction of nuclear EGR-1
protein, we observed a significant decrease in Mt1 mRNA.
Allowing for a delay between Mt1 transcriptional inhibition and
decrease in steady state mRNA levels, the relative time course of
Figure 3. Regulation of rat Mt1 promoter activity by PITX-1 and EGR-1 in vitro. COS-7 cells were co-transfected with an Mt1-luciferase
reporter construct and a combination of control vector, PITX-1 expression vector and EGR-1 expression vector. Horizontal bars indicate mutagenesis
of PITX-1 and EGR-1 binding sites. P1: distal PITX-1 consensus site; P2: proximal PITX-1 consensus site; E: EGR-1 consensus site. *** p,0.001 vs control
group; ### p,0.001 vs PITX-1 group (one-way ANOVA with Bonferroni post-hoc test).
doi:10.1371/journal.pone.0090056.g003
Figure 4. Pituitary Mt1 expression is unaltered in adult Egr-12/2
mice. Brain and pituitary tissue from adult wild type (WT) and Egr-12/2
mice was dissected with the pituitary stalk intact, frozen on dry ice and
stored at 280uC. Twenty micron sagittal sections were cut and Mt1
mRNA expression determined by in situ hybridisation histochemistry.
Quantification of Mt1 expression by densitometry revealed no
significant difference (p.0.05 unpaired t-test) of genotype. Represen-
tative autoradiographs are shown above the respective bar.
doi:10.1371/journal.pone.0090056.g004
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these events may be consistent with a functional relationship
between EGR-1 and Mt1 in perinatal gonadotroph cells. The half
life of Mt1 mRNA is estimated to be 2–3 hours in ovine pars
tuberalis cells [28]. Despite differences in cell type and unknown
extent of transcriptional repression in our GnRH-treated aT3-1
cells, the timing of Mt1 inhibition is not inconsistent with its
estimated half life. However, attempts to demonstrate a causal
relationship between these events were prevented by an inability to
transfect the aT3-1 cells with inhibitors of EGR-1 expression or
function.
Our previous in vivo data demonstrated that adult rodents
unable to synthesise GnRH throughout development exhibit
elevated pituitary Mt1 expression [20], but the regulation of Mt1
by GnRH signalling in adulthood is unknown. We therefore next
investigated the effect of a GnRH receptor antagonist, cetrorelix,
on Mt1 expression in the adult rat pituitary. Daily intra-peritoneal
injections of cetrorelix successfully shut-down the rats’ reproduc-
tive system, as demonstrated by analysis of serum LH concentra-
tion and testis morphology. However, despite this physiological
effect, there was surprisingly no change in pituitary Mt1
expression. This finding contrasts with the ability of cetrorelix to
induce MT1 receptor expression in the GT1-7 neuronal cell line
[29] and suggests that changes during normal gonadotroph
development maintain inhibition of Mt1 mRNA, despite the lack
of GnRH signalling.
A limitation of the current study is that our in situ hybridisation
protocol measured gene expression in all cell types present in the
tissue sections and not just gonadotroph cells. However, to explain
our cetrorelix data, any elevation of gonodotroph Mt1 mRNA
caused by the treatment would have to be mirrored by an equal
decrease in Mt1 expression within other cell types. Moreover, the
increased Mt1 mRNA observed in hypogonadal mice was readily
detectable by the same in situ hybridisation protocol [20]. The
most likely explanation of our results is therefore that cetrorelix
had no effect on gonadotroph Mt1 expression in the adult rat
pituitary. It also remains possible that adult mice treated with
cetrorelix may exhibit a similar increase in pituitary Mt1 mRNA
expression as we previously observed in hypogonadal mice. However
the species-specific mechanisms that could cause such a difference
are unclear.
We next extended previous analyses of rat Mt1 promoter
activity in vitro. As shown previously [20], over-expression of
PITX-1 induces activity of a 2445 bp Mt1-luciferase construct
and this PITX-1-stimulated activity is strongly inhibited by co-
transfection with an EGR-1 expression vector. The ability of
PITX-1 to stimulate Mt1 promoter activity was inhibited by
mutagenesis of either of its consensus sequences, indicating that
both are required for successful promoter activation. However,
EGR-1 retained its ability to inhibit PITX-1-stimulated promoter
activity even after mutation of its consensus binding sequence.
This finding suggested that, in our in vitro system, EGR-1 is able
to inhibit Mt1 promoter activity without binding to DNA and thus
presumably via protein-protein interactions. Such a mechanism
would be consistent with reports of functional interactions between
EGR-1 and other proteins involved in transcriptional regulation
[27,30–33].
Finally, in order to investigate the role of EGR-1 in melatonin
receptor regulation in vivo, we examined Mt1 expression in the
pituitary of Egr-12/2 mice. As observed previously [20], adult wild
type mice exhibited weak pituitary Mt1 expression. In contrast to
the upregulation of Mt1 in hypogonadal mice that are unable to
synthesise GnRH, and despite inhibition of Mt1 promoter activity
by EGR-1 in vitro, there was no difference in pituitary Mt1
expression between Egr-12/2 mice and wild type litter mates.
Thus, despite the ability of EGR-1 over-expression to inhibit Mt1
promoter activity in vitro, EGR-1 is not necessary for GnRH to
regulate Mt1 in vivo. One possible explanation for this finding is
that there is developmental compensation in the knock-out model
[34]. However, Egr-12/2 mice remain infertile due to a lack of LH
synthesis [35,36], indicating that developmental compensation
within the pituitary would have to be specific for Mt1 regulation. A
second and perhaps more likely explanation for the absence of an
effect of genotype is that additional pathway(s) link GnRH
signalling to Mt1 expression, thus providing functional redundancy
of signal transduction mechanisms. At present we are unable to
distinguish between these possibilities.
In summary, we have provided novel information describing the
regulation of pituitary Mt1 melatonin receptor mRNA, both in
vivo and in vitro. Although underlying signal transduction
mechanisms are unclear, our current data expand upon previous
work and reveal a direct ability of GnRH signalling to down-
regulate melatonin receptor expression in aT3-1 gonadotroph
cells. Despite this effect and the elevated Mt1 previously observed
in hypogonadal mice, blockade of GnRH signalling in adult animals
didn’t increase pituitary Mt1 mRNA. Together these findings
suggest that GnRH may induce a long-term change in melatonin
sensitivity, rather than merely a tonic inhibition of gene
transcription. As discussed elsewhere [21], the developmental
timing of pituitary melatonin receptor down-regulation is similar
to the onset of hypothalamic GnRH signalling in rodents and
sheep, which have greatly differing gestational lengths. Moreover,
rat and ovine Mt1 promoters possess some common regulatory
elements [20,21]. The findings presented herein may therefore be
relevant to multiple mammalian species.
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